Q-omics provides the consensus-scored AGPAT3 profile across patient tissues and cancer cell-line models. AGPAT3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AGPAT3 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, AGPAT3 protein abundance shows 20,641 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where AGPAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGPAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGPAT3 survival associations across molecular data types. AGPAT3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGPAT3 RNA expression–survival associations across cancer types. High AGPAT3 expression shows unfavorable associations in UVM, CESC, ACC, LAML and UCS, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AGPAT3 RNA expression.
This table summarizes AGPAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AGPAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGPAT3 shows lower tumor expression in THCA and KICH and higher tumor expression in UCEC, STAD, BRCA and LIHC. The THCA box plot shows higher AGPAT3 RNA expression in normal versus tumor tissue (log2 FC = −0.865, t-test p < 0.001).
This table shows molecular features associated with AGPAT3 in patient tissues and cancer cell lines. In patient samples, AGPAT3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGPAT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
